During the past decade, Lions Eye Institute conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Lions Eye Institute" are "Geographic Atrophy" (1 trials) and "Macular Degeneration" (1 trials). Many other conditions were trialed in "Lions Eye Institute" in a lesser frequency.

Most popular intervention types in "Lions Eye Institute" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Lampalizumab" (1 trials) and "rhuFab V2 (ranibizumab)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lions Eye Institute" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Lions Eye Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Lions Eye Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Lions Eye Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".